Paris. Tuesday 6 September 2016, 07:00 BST. SpineVision® SA and Norgine Ventures B.V. today announced they have entered into a definitive agreement under which Norgine Ventures acquired SpineVision®.
SpineVision® is an integrated spinal technology company focused on the development and marketing of implants and instrumentation for spinal treatment.
Arnaud Brisard, Chief Executive Officer, SpineVision® commented “I am delighted that SpineVision® is now fully financed and backed by Norgine Ventures, a company that is a strong partner in the healthcare sector. This will enable us to strengthen our research and development and ultimately grow the commercial activity of our unique products combining dynamic stabilization and a minimally invasive approach.”
Notes to Editors:
For further information please contact:
Arnaud Brisard, SpineVision®, +33(0)220.127.116.11.26, [email protected]
SpineVision® is a privately-owned integrated spinal technology company focused on the development and marketing of implants and instrumentation for spinal treatment.
Since its foundation in 1999, the company has designed innovative products which offer key advantages to surgeons and benefits to patients. SpineVision’s current products offer solutions for approximately 90% of spinal pathologies i.e. lumbar degenerative disc diseases, deformities, cervical disorders, trauma and tumors. With its new generation products Flex+2 and LUMIS SpineVision® is the only manufacturer offering a dynamic stabilization system which can be used in a percutaneous approach.
The Company is headquartered in Antony (south of Paris), France, and has subsidiaries in the USA, Germany, Italy, Belgium and UK.
For more information, please visit http://www.spinevision.com/
About Norgine Ventures
Norgine Ventures was started in 2012 to diversify Norgine’s activities and to foster innovation in the healthcare sector. Norgine Ventures provides debt and debt-like financing to innovative, fast growing companies in the fields of healthcare and life sciences, in Europe and in the US.For more information: www.norgineventures.com
Norgine is a European specialist pharmaceutical company that has been established for over 110 years. In 2015, Norgine’s total revenue was EUR 320 million and the company employs over 1,000 people.
Norgine provides expertise and ‘know how’ in Europe to develop, manufacture and market products that offer real value to healthcare professionals, payers and patients. Norgine’s approach and infrastructure is integrated and focused upon ensuring that Norgine wins partnership opportunities for growth.
For more information: www.norgine.com
NORGINE and the sail logo are trademarks of the Norgine group of companies.